MARKET

SLS

SLS

Sellas Life Sciences Group Inc
NASDAQ
2.340
+0.230
+10.90%
Pre Market: 2.290 -0.05 -2.14% 04:34 12/19 EST
OPEN
2.160
PREV CLOSE
2.110
HIGH
2.390
LOW
2.160
VOLUME
760
TURNOVER
0
52 WEEK HIGH
2.480
52 WEEK LOW
0.8335
MARKET CAP
333.31M
P/E (TTM)
-8.1533
1D
5D
1M
3M
1Y
5Y
1D
Unusually active option classes on open December 17th
TipRanks · 1d ago
Weekly Report: what happened at SLS last week (1208-1212)?
Weekly Report · 4d ago
Unusually active option classes on open December 8th
TipRanks · 12/08 14:40
SELLAS Rises On Positive Phase 2 Data Of SLS009 In Relapsed/Refractory AML-MR
NASDAQ · 12/08 10:47
Weekly Report: what happened at SLS last week (1201-1205)?
Weekly Report · 12/08 09:33
Sellas Life Sciences presents Phase 2 study of SLS009
TipRanks · 12/08 01:45
SELLAS Life Sciences Announced Sunday, SLS009 In Combination With AZA/VEN Achieved 46% Overall Response Rate Across All Cohorts, 58% Overall Response Rate In Patients With One Prior Line Of Therapy In AML-MR Study
Benzinga · 12/07 23:25
Sellas Life Sciences Announces Positive Phase 2 Results for SLS009 Combination in Relapsed AML
Reuters · 12/07 23:00
More
About SLS
SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the development of therapeutics for a range of cancer indications. The Company's product candidates are galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1 (WT1), antigen, and SLS009, a selective small molecule cyclin-dependent kinase 9 (CDK9) inhibitor. GPS is a cancer immunotherapeutic agent licensed by Memorial Sloan Kettering Cancer Center (MSK), that targets the WT1 protein, which is present in an array of tumor types. GPS has potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic malignancies and solid tumor indications. The Company is developing SLS009, which is licensed by GenFleet Therapeutics (Shanghai), Inc., for all therapeutic and diagnostic uses in the world outside of mainland China, Hong Kong, Macau, and Taiwan.

Webull offers Sellas Life Sciences Group Inc stock information, including NASDAQ: SLS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SLS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SLS stock methods without spending real money on the virtual paper trading platform.